Nuvation Bio (NUVB) Liabilities and Shareholders Equity (2020 - 2026)

Nuvation Bio (NUVB) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $610.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 23.91% year-over-year to $610.2 million; the TTM figure through Mar 2026 stood at $2.5 billion (up 11.56% YoY), while the FY2025 annual figure was $594.8 million, up 10.02% from the prior year.
• Liabilities and Shareholders Equity advanced to $610.2 million in Q1 2026 per NUVB's latest filing, from $594.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $751.8 million in Q1 2022 and bottomed at $492.5 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $626.3 million across 5 years, with a median of $621.5 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity retreated 19.68% — and 2026, when it climbed 23.91%.
• Nuvation Bio's Liabilities and Shareholders Equity stood at $672.1 million in 2022, then fell by 7.54% to $621.5 million in 2023, then slipped by 13.01% to $540.6 million in 2024, then grew by 10.02% to $594.8 million in 2025, then rose by 2.59% to $610.2 million in 2026.
• Business Quant data shows NUVB's Liabilities and Shareholders Equity at $610.2 million in Q1 2026, $594.8 million in Q4 2025, and $601.6 million in Q3 2025.